Title:
Adverse Drug Reactions Following Propranolol in Infantile Hemangioma

dc.contributor.authorVaibhav Pandey
dc.contributor.authorPreeti Tiwari
dc.contributor.authorMohammed Imran
dc.contributor.authorAkash Mishra
dc.contributor.authorDeepak Kumar
dc.contributor.authorS.P. Sharma
dc.date.accessioned2026-02-07T10:38:58Z
dc.date.issued2021
dc.description.abstractObjectives: To assess the adverse effects of propranolol therapy in infantile hemangioma. Methods: An ambispective study was conducted from August 2011 to December 2019. In retrospective arm all children managed for infantile hemangioma with propranolol were included and case records were assessed for adverse reactions. In prospective arm the adverse reactions were identified on the basis of predefined criteria. Results: A total of 514 patients (358 retrospective records) were included. A majority, 378 (73.5%) patients had an excellent response, 75 (14.5%) had partial response and 61 (11.8 %) had no response. A total of 82 (15.9%) patients experienced at least one adverse effect. Diarrhea with weight loss (27, 32.9%) and irritability with decreased sleep (21, 25.6%) were the most common adverse effects. The adverse effects in 22 (4.2%) cases lead to the discontinuation of propranolol. Younger age, low body weight and early onset were risk factors for development of severe adverse reactions. Conclusion: Young children with low body weight were at higher risk for adverse effects of propranolol. © 2021, Indian Academy of Pediatrics.
dc.identifier.doi10.1007/s13312-021-2286-3
dc.identifier.issn196061
dc.identifier.urihttps://doi.org/10.1007/s13312-021-2286-3
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/37402
dc.publisherSpringer
dc.subjectBeta blocker
dc.subjectDiarrhea
dc.subjectHypoglycemia
dc.subjectSevere ADR
dc.subjectWeight loss
dc.titleAdverse Drug Reactions Following Propranolol in Infantile Hemangioma
dc.typePublication
dspace.entity.typeArticle

Files

Collections